Health utility values measured by EQ-5D in patients with Alzheimer’s disease: a systematic review and meta-analysis
This systematic review and meta-analysis of 20 studies reveals that EQ-5D utility values for Alzheimer's disease are highly context-dependent, varying significantly by disease severity, respondent type, and regional tariffs, with a notably sharp decline in quality of life as the condition progresses from moderate to severe stages.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Alzheimer's disease is a progressive condition that slowly erodes a person's memory, thinking, and ability to care for themselves. As the disease advances, it transforms daily life, turning simple tasks into impossible challenges and altering the rhythm of a person's existence. For doctors, policymakers, and families trying to decide how to spend limited healthcare resources, there is a need to measure the value of life with this illness. They do not just count the years a person lives; they try to weigh the quality of those years. To do this, researchers use a tool called a "health utility" score. Imagine a scale where zero represents a state of death and one represents perfect health. Every moment spent with a health condition falls somewhere between those two points. This score helps calculate "quality-adjusted life years," a way to compare the benefit of different medical treatments. If a new drug can keep a patient in a better state of health for longer, it earns more points on this scale, helping decision-makers understand if the cost of the drug is worth the improvement in life.
However, getting an accurate score for Alzheimer's has been difficult because the experience of the disease varies so wildly. A person in the early stages might feel only slightly different from their usual self, while someone in the final stages may be completely dependent on others. Furthermore, who is asked to give the score matters immensely. A patient might feel their life is still meaningful despite their memory loss, while a caregiver watching the same person struggle with basic needs might rate the quality of life much lower. Because these scores are the foundation for economic studies that determine which treatments get funded, a team of researchers set out to gather every available measurement to find a clearer picture. They wanted to know if there was a single, standard number that could describe the quality of life for someone with Alzheimer's, or if the answer depended entirely on the specific circumstances of the patient and the observer.
The researchers conducted a massive review, searching through thousands of scientific records to find studies that had measured these health scores in people with Alzheimer's. They looked for data from clinical trials, long-term observations, and surveys from around the world. After filtering out studies that did not provide the necessary details, they analyzed data from twenty different studies involving more than six thousand people. Their goal was to combine these numbers to see what the average health score looked like and to understand why the numbers differed so much from one study to the next.
The analysis revealed that there is no single, fixed number for Alzheimer's. The average health score across all the studies was 0.686, which sits comfortably below perfect health but well above the lowest possible state. However, this average masked a complex reality. The researchers found that the score dropped sharply as the disease became more severe. People with mild Alzheimer's had a score of 0.787, indicating a relatively high quality of life. Those with moderate disease saw a slight drop to 0.721. But for those with severe Alzheimer's, the score plummeted to 0.422. The decline between the moderate and severe stages was nearly five times larger than the drop between mild and moderate, suggesting a steep cliff in quality of life once the disease reaches its most advanced stage.
Who was asked to provide the score also made a huge difference. When patients rated their own health, the average score was 0.766. When caregivers or family members rated the same patients, the score was significantly lower at 0.592. This gap suggests that people living with the disease may adapt to their condition and find value in their lives that an outside observer cannot see, or that caregivers focus more heavily on the visible struggles and losses. The study also showed that where the research took place mattered, with scores generally lower in Asia compared to Europe and North America, and that the specific method used to calculate the score influenced the results.
The researchers concluded that using a single, generic number to represent Alzheimer's in economic models is misleading. Instead, the value of a patient's life depends heavily on the stage of their disease, who is doing the rating, and the specific context of their care. For new treatments that aim to slow down the progression of the disease rather than cure it, this distinction is vital. If a drug can keep a patient from sliding from the moderate stage to the severe stage, the benefit is enormous because that transition represents a massive drop in quality of life. By understanding these nuances, health officials can make better decisions about which treatments truly improve lives and how to allocate resources to support those living with this challenging condition.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.